ARA-290 Research Peptide

Yes. Every batch of ARA-290 is tested by an independent third-party laboratory using HPLC and MS-UPLC, confirming purity and mass identity before the batch is released. Pure Peptides does not test its own material.

Yes. The Certificate of Analysis for the batch currently in stock can be viewed and downloaded directly on this page, before you place an order. Each certificate states the batch number, the measured purity, and the date of analysis, and can be verified independently with the issuing laboratory using the report number it carries.

It means ARA-290 is supplied for in-vitro laboratory research and for no other purpose, and must not be administered to humans or animals. ARA-290 is legal to purchase in the United States for in vitro and non-clinical laboratory research. It has no FDA approval and no approved human use. ARA-290 is not a scheduled substance under the Controlled Substances Act. Sold strictly for qualified research use, not human or veterinary administration.

ARA-290 ships from US stock with cold-chain packaging and full tracking; orders placed before noon EST on business days are typically dispatched the same business day. On arrival, store the lyophilized powder at -20°C or below, dry and protected from light.

Yes. They are two names for the same eleven-residue peptide, and the published literature is split between them. Searching one name misses a large part of the field. The Published Research tab names which term each cited study used.

Yes, at phase 2. Two trials in sarcoidosis-associated small fiber neuropathy reported improvements, one in a 22-patient pilot and one in a 64-patient trial where the middle of three doses increased corneal nerve fiber area significantly and the doses either side of it did not. In the same trial, pain improved in every group including placebo. A separate 12-week trial in diabetic macular edema found no change on its main measures and reported no safety problems. The Published Research tab gives the numbers for all three.